title: Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.
abstract: OBJECTIVE
  Atomoxetine's tolerance and efficacy were studied in 24 patients with pervasive developmental disorder and symptoms of ADHD.
  
  
  METHODS
  Prospective, open-label, 16-week study was performed, using the variables of the Clinical Global Impression Scale and the Conners' Scale, among others.
  
  
  RESULTS
  A significant difference was found between pre- and posttreatment scores as well as a significant reduction was found on the scales used. Only five patients presented adverse events.
  
  
  CONCLUSIONS
  Atomoxetine therefore appears to be a useful drug, pointing to the need for larger, randomized, controlled, double-blind studies to confirm its efficacy versus placebo and in comparison with other treatment options.
authors.affiliation: Hospital Universitario Quirón, Madrid, Spain. aferjaen@telefonica.net
authors.forename: Alberto
authors.initials: A
authors.lastname: Fernández-Jaén
authors.forename: Daniel Martín
authors.initials: DM
authors.lastname: Fernández-Mayoralas
authors.forename: Beatriz
authors.initials: B
authors.lastname: Calleja-Pérez
authors.forename: Nuria
authors.initials: N
authors.lastname: Muñoz-Jareño
authors.forename: María del Rosario
authors.initials: Mdel R
authors.lastname: Campos Díaz
authors.forename: Sonia
authors.initials: S
authors.lastname: López-Arribas
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy* / Q000453:epidemiology; D002675:Child, Preschool; D015897:Comorbidity; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010865:Pilot Projects; D011437:Propylamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride